The BAP is a learned society and registered charity. It promotes research and education in psychopharmacology and related areas, and brings together people in academia, health services, and industry. Formed in 1974, it is the largest such national association in Europe, and the second largest in the world.
BAP2020Join us as we return to London for our annual Summer Meeting, 19th - 22nd July
BAP Outstanding Contribution AwardNominations are now open for the 2020 Outstanding Contribution Award
BAP Summer Research Internship SchemeNew BAP Summer Research Internship Scheme for pre-doctoral researchers
Pocket Prescriber PsychiatryThe new Pocket Prescriber Psychiatry book is out now.
Visualising Psychotropic Medicine (VPM)Presenting what can be a complex set of data in a useful and engaging way
Online CPD ResourceRCPsych Online CPD Subscribers get a discount on the BAP Online Resource
Fundamentals of Clinical PsychopharmacologyBuy a discounted copy of the latest edition of Fundamentals of Clinical Psychopharmacology
Neuroscience-based Nomenclature (NbN) for JoPJournal of Psychopharmacology chosen to trial new NbN
Not all in the mind – the contribution of brain science to modern psychiatryWatch Prof David Nutt's lecture in Manchester on YouTube
Benefits of BAP membership include:
- FREE subscription and access to the Journal of Psychopharmacology (published monthly online).
- Reduced registration fees for the annual Summer Meeting.
- Half price subscription to the Online CPD Resource.
- Eligibility for prizes and awards.
- Student bursaries for the BAP Summer Meeting and international conferences.
- Reduced registration fees for selected partner association events.
- 50% OFF Royal Society of Biology membership (Read more)
- BAP Newsletter.
- Voting for BAP Officers and Council (full members only).
- Being part of one of the largest national psychopharmacology associations in the world.
|8th March 2020||Certificate in Non-Clinical Psychopharmacology - Residential Course||The Royal Cambridge Hotel|
|26th March 2020||Child and Adolescent Psychopharmacology||Park Plaza Hotel, Maid Marian Way, Nottingham|
|22nd April 2020||Day A: Schizophrenia / Substance Use Disorders and Comorbidity||Hallam Conference Centre 44 Hallam Street London|
Nocturnal light exposure and mood disorders
By Antonio Gonzalez
Posted on 9th December 2019
Introduction For millions of years prior to the widespread use of electricity, humans were exposed to minimal amounts of nocturnal light in comparison to modern times. During clear starry nights, light exposure was limited to around 0.001 lux, and no artificial light sources existed until the use of fire, an ability that is estimated to […]
Deciphering the biology behind psychiatric risk genes
By Simon Trent
Posted on 12th November 2019
Genetic studies that scan the genomes of psychiatric patients are becoming increasingly good at identifying ‘risk genes’ associated with disorders such as schizophrenia, autism and intellectual disability. However, we still know very little about the biological actions and pathways that are being genetically encoded within these risk genes. Understanding the biology behind the vulnerability to […]
The neuroeconomics of drug use
By Will Lawn
Posted on 15th October 2019
Neuroeconomics is an interdisciplinary research field, which emerged in the early 2000s, made up of a combination of cognitive neuroscience, psychology and behavioural economics. The primary aims of neuroeconomics are to: identify which brain regions encode subjective value (Chib, Rangel, Shimojo, & O’Doherty, 2009; Peters & Büchel, 2010); understand the brain mechanisms that underpin decision-making […]
Talks at Google: Sex, Lies, and Brain Scans: How fMRI Reveals What Really Goes on in Our Minds
Barbara Sahakian visits Talks at Google to discuss her book "Sex, Lies, and Brain Scans: How fMRI Reveals What Really Goes on in Our Minds"
24th January 2020
BBC World Service History Hour: The Awakenings
Jonathan was interviewed about encephalitis lethargica, modern-day catatonia and the exciting results of contemporary psychopharmacological treatment
17th December 2019
One-off ketamine dose may reduce heavy drinking, say scientists
Ravi speaks to the Guardian about a new study using ketamine to help heavy drinkers
26th November 2019
Welcome to the World of George the Poet
Akeem Sule and Becky Inkster (Hip Hop Psych) interview George the poet on hiphop and mental health
2nd November 2019
5 News Special - Mental Health - Breaking the Silence
Andrew focuses specifically on fathers in a Channel 5 News programme dedicated to men’s mental health.
30th July 2019
|BMA Foundation for Medical Research Grants opening 1 January 2020 |
17th December 2019
Online applications will open 1 January and close on 6 March 2020
|2019 Prizes and Awards |
25th July 2019
View all award winners from this year's meeting. Photos, reflections and biographies are being continually updated, so check back often.
View this year's prize winners
|Street Drugs Conference Wales 2019: Is the Dragon Still Smoking? |
13th July 2019
Overview of the latest Street Drugs Conference in Wales on 25th June.
Read the review
|REF2021 Success |
4th February 2019
Prof Allan Young, Prof Jeremy Hall and Prof Helen Cassaday selected to join REF2021 panel 4: Psychology, Psychiatry and Neuroscience
Psychopharmacology is the study of drugs that affect mood, behaviour and cognition. It aims to develop our understanding of the actions and effects of such drugs, which may include treatments for psychiatric disorders as well as substances that can be abused.